Alternatives to Animal Testing and Experimentation
Online ISSN : 2185-4726
Print ISSN : 1344-0411
ISSN-L : 1344-0411
Volume 16, Issue 3
Displaying 1-2 of 2 articles from this issue
REVIEW
  • Michael Balls
    Article type: Review
    2011 Volume 16 Issue 3 Pages 101-110
    Published: December 31, 2011
    Released on J-STAGE: January 23, 2012
    JOURNAL FREE ACCESS
    Progress in the development and application of replacement alternative methods is discussed, with particular reference to the new technologies and their use in current initiatives to tackle the problem of drug-induced liver injury. The formidable challenges involved are discussed in terms of improving our understanding of the immense puzzles to be solved, our inability to control events, and the law of unintended consequences. Nevertheless, the future is bright, and the reign of the animal-models-tell-us-all and one-drug suits-all philosophies is rapidly coming to an end.
    Download PDF (128K)
ORIGINAL ARTICLE
  • Masakazu Katoh, Kenichiro Hata
    Article type: Original Article
    2011 Volume 16 Issue 3 Pages 111-122
    Published: December 31, 2011
    Released on J-STAGE: January 23, 2012
    JOURNAL FREE ACCESS
    A validation study of an in vitro skin irritation test (SIT) method using a reconstructed human epidermal (RhE) model for replacement of the Draize test was conducted by the European Centre for the Validation of Alternative Methods (ECVAM), and a protocol using an RhE model, EpiSkinTM (SkinEthic, France), was approved as a validated reference method (VRM) in April, 2007. Structural and performance test criteria for skin models are defined in the ECVAM Performance Standards. We have performed several evaluations of our RhE model, LabCyte EPI-MODEL24 (Japan Tissue Engineering Co., Ltd, Japan), and have confirmed the original LabCyte EPI-MODEL24 SIT method defined by the ECVAM Performance Standards. However, the original LabCyte EPI-MODEL24 SIT might not meet with OECD test guideline 439 (OECD TG439) defining the SIT method used with a RhE model, which was newly adopted in July, 2010. This is because the original LabCyte EPI-MODEL24 SIT method predicted 1- bromohexane as a false-negative, which is one of the reference chemicals listed in OECD TG439 but OECD TG439 doesn't allow a SIT which predicts a false-negative except for some specific reference chemicals. In the present study, various modifications of the original LabCyte EPI-MODEL24 SIT have been examined in order to solve the misclassification of 1-bromohexane showing up as a false-negative, and it was found that the misclassification could be corrected by modifying the washing protocol for test chemicals (the modified LabCyte EPI-MODEL24 SIT). When the predictive potency of the modified LabCyte EPI-MODEL24 SIT was evaluated with the 20 reference chemicals listed in the new OECD TG439 for in vitro skin irritation testing, which was adopted in July 2010, the sensitivity, specificity and overall accuracy were 90 %, 70 %, and 80%, respectively. It is thought that these results meet the acceptance criteria described in OECD TG439.
    Download PDF (380K)
feedback
Top